摘要
目的探究小儿清炎合剂(716合剂)治疗呼吸道合胞病毒所致呼吸道感染疗效观察及血清学研究。方法将2023年1月至2023年9月江西省儿童医院收治的呼吸道合胞病毒所致呼吸道感染的80例患儿作为研究对象,根据随机对照表法将其分为观察组40例,对照组40例。对照组采用雾化吸入联合静脉输液进行治疗,观察组在对照组的基础上口服小儿清炎合剂(716合剂)。比较两组的临床疗效,治疗前后炎性因子[白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、C反应蛋白(CRP)、血清淀粉样蛋白A(SAA)、肿瘤坏死因子-α(TNF-α)],免疫功能水平(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)),恢复情况和不良反应。结果观察组治疗有效率为95.00%,高于对照组的80.00%(P<0.05)。治疗后,两组IL-6、IL-10、CRP、SAA、TNF-α水平均下降且观察组低于对照组(P<0.05);观察组CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,而观察组CD8^(+)水平低于对照组(P<0.05)。观察组退热、止咳、平喘以及住院时间均小于对照组(P<0.05)。两组在治疗过程中均未出现任何不良反应。结论小儿清炎合剂(716合剂)能够缓解呼吸道合胞病毒感染患儿的炎性症状,增强患儿免疫功能,促进患儿恢复,安全性良好。
Objective To explore the efficacy observation and serological study of xiao’er qingyan mixture(716 mixture)in the treatment of respiratory tract infection caused by respiratory syncytial virus.Methods 80 children with respiratory tract infection caused by respiratory syncytial virus admitted to Jiangxi Children's Hospital from January 2023 to September 2023 were selected as the research subjects.According to the random control table,they were divided into observation group(40 cases)and control group(40 cases).The control group was treated with nebulized inhalation combined with intravenous infusion,while the observation group was given administration of xiao’er qingyan mixture(716 mixture)on the basis of the control group.Compare the clinical efficacy,inflammatory factors[interleukin-6(IL-6),interleukin-10(IL-10),C-reactive protein(CRP),serum amyloid A(SAA),tumor necrosis factor-α(TNF-α)],immune function levels(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)),recovery situation and adverse reactions before and after treatment between the two groups.Results The total effective rate of treatment in observation group was 95.00%,which was higher than 80.00%in control group(P<0.05).After treatment,the levels of IL-6,IL-10,CRP,SAA,TNF-αwere decreased in the two groups,and the observation group had lower levels(P<0.05).The levels of CD4^(+)and CD4^(+)/CD8^(+)in observation group after treatment were higher than those in control group while the level of CD8^(+)was lower than that in control group(P<0.05).The observation group had shorter fever abatement time,cough relief time,asthma relief time and hospital stay(P<0.05).No adverse reactions occurred in the two groups during treatment.Conclusion Xiao’er qingyan mixture(716 mixture)can relieve the inflammatory symptoms,enhance the immune function,promote the recovery of children with respiratory syncytial virus infection,with good safety.
作者
胡晓璐
李剑
杜云
杨细媚
杨长存
杨青青
HU Xiaolu;LI Jian;DU Yun;YANG Ximei;YANG Changchun;YANG Qingqing(Jiangxi Provincial Children's Hospital,Nanchang Jiangxi 330006,China;Nanchang 334 Hospital,Nanchang Jiangxi 330001,China)
出处
《药品评价》
CAS
2024年第4期443-446,共4页
Drug Evaluation
基金
2023年度江西省中医药管理局科技计划项目(2023B0186)。
关键词
小儿清炎合剂
呼吸道感染
呼吸道合胞病毒
疗效观察
儿童
Xiao’er qingyan mixture
Respiratory tract infection
Respiratory syncytial virus
Efficacy observation
Children
